Ozempic, Wegovy might lower colon cancer risk
Ozempic and Wegovy might help people avoid colon cancer as well as promote weight loss or control diabetes, a new study says.
Jan 7, 2026
0
15
Amino Acids, Peptides, and Proteins: News and Research on Gastric Inhibitory Polypeptide
MeSH tree: D12.776.631.650.300
How eggs can help you come off Wegovy: Cracking the problem of weight-regain
For millions of people, weight-loss injections such as Wegovy and Mounjaro have felt like a breakthrough that finally makes eating less feel easier. In a few short years, these so-called GLP-1 drugs have reshaped how obesity ...
Jan 6, 2026
0
9
Tirzepatide noninferior to dulaglutide for CV outcomes in type 2 diabetes
Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic CV disease, according ...
Dec 30, 2025
0
16
Private health insurance costs are going up: A complete guide to coverage options
Private health insurance premiums will be going up in 2026—in some cases, by a lot.
Dec 16, 2025
0
27
My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs
Even when Americans have health insurance, they can have a hard time affording the drugs they've been prescribed.
Dec 16, 2025
0
6
GLP-1 diabetes drugs linked to lower epilepsy risk in large study
A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published in Neurology.
Dec 10, 2025
0
15
GLP-1 receptor agonists likely have little or no effect on obesity-related cancer risk, research shows
A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or overweight or obesity.
Dec 8, 2025
0
14
One in four with type 2 diabetes faces muscle loss and worse outcomes
In a new paper published in Clinical Nutrition, "Sarcopenic Diabetes Is an Under-Recognized and Unmet Clinical Priority," nutrition and diabetes experts are calling attention to a little-known but serious complication of ...
Dec 1, 2025
0
19
WHO recommends Ozempic-style weight loss drugs for obesity
Obesity affects more than 1 billion people worldwide and is recognized by the World Health Organization as a chronic, relapsing disease associated with substantial morbidity, mortality, and economic burden.
Dec 1, 2025
0
25
Tirzepatide's benefits fade for most: Weight and health markers rebound after withdrawal, study finds
Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide patients. People with obesity ...
